Clinical Trial Update: Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Y-90 ibritumomab tiuxetan with rituximab for relapsed or refractory diffuse large B-cell non-Hodgkin's lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Non-hodgkin Lymphoma
• Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• Y-90 ibritumomab tiuxetan (ibritumomab tiuxetan)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2018-01-23